‘In A Word, Complicated’ – AAM’s Burton Talks US Biosimilars
Biosimilars Council Chief Sees Improvement In US Market, But Says There Is Further To Go
Executive Summary
With the first US Humira rival having just hit the market and biosimilars seeing increasing adoption overall, Craig Burton – executive director of the AAM’s Biosimilars Council – says that the US biosimilars market is ‘doing better, but we still have improvements to make.’
You may also be interested in...
Amgen Talks Dual Pricing Strategy For Amjevita
In the wake of Amgen announcing a dual pricing strategy for its debut US adalimumab biosimilar – with the firm’s newly-launched Amjevita version being offered at both 5% off and 55% off the WAC of the Humira original – investors and analysts were keen to press the firm for further details of its pricing strategy.
Confusion Persists Over US Biosimilar Interchangeability
The US biosimilars industry is being constrained by misunderstandings stemming from the country’s interchangeability designation, a new paper in BioDrugs has highlighted, citing an urgent need for clarity over the misperception that interchangeable biosimilars are superior to biosimilars without the designation.
Samsung Bioepis Goes After Lucentis With 40% Cheaper Byooviz Launch In US
Samsung Bioepis and Biogen have come in with a hefty discount as they mark a major milestone by launching their Byooviz biosimilar ranibizumab rival to Lucentis in the US.